<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37261215</PMID><DateRevised><Year>2023</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-7762</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Lancet regional health. Europe</Title><ISOAbbreviation>Lancet Reg Health Eur</ISOAbbreviation></Journal><ArticleTitle>Differences in incidence, nature of symptoms, and duration of long COVID among hospitalised migrant and non-migrant patients in the Netherlands: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>100630</StartPage><MedlinePgn>100630</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100630</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lanepe.2023.100630</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Comprehensive data on long COVID across ethnic and migrant groups are lacking. We investigated incidence, nature of symptoms, clinical predictors, and duration of long COVID among COVID-19 hospitalised patients in the Netherlands by migration background (Dutch, Turkish, Moroccan, and Surinamese origin, Others).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We used COVID-19 admissions and follow up data (January 2021-July 2022) from Amsterdam University Medical Centers. We calculated long COVID incidence proportions per NICE guidelines by migration background and assessed for clinical predictors via robust Poisson regressions. We then examined associations between migration background and long COVID using robust Poisson regressions and adjusted for derived clinical predictors, and other biologically relevant factors. We also assessed long COVID symptom persistence at one-year post-discharge.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">1886 patients were included. 483 patients had long COVID (26%, 95% CI 24-28%) at 12 weeks post-discharge. Symptoms like dizziness, joint pain, insomnia, and headache varied by migration background. Clinical predictors of long COVID were female sex, hospital admission duration, intensive care unit admission, and receiving oxygen, or corticosteroid therapy. Long COVID risk was higher among patients with migration background than Dutch origin patients after adjustments for derived clinical predictors, age, smoking, vaccination status, comorbidities and remdesivir treatment. Only 14% of long COVID symptoms persisted at one-year post-discharge.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">There are significant differences in occurrence, nature of symptoms, and duration of long COVID by migration background. Studies assessing the spectrum of functional limitation and access to post-COVID healthcare are needed to help plan for appropriate and accessible healthcare interventions.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">The Amsterdam UMC COVID-19 biobank is supported by the Amsterdam UMC Corona Research Fund and the Talud Foundation (Stichting Talud). The current analyses were supported by the Novo Nordisk Foundation [NNF21OC0067528].</AbstractText><CopyrightInformation>&#xa9; 2023 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chilunga</LastName><ForeName>Felix Patience</ForeName><Initials>FP</Initials><AffiliationInfo><Affiliation>Department of Public and Occupational Health, Amsterdam Public Health, University of Amsterdam Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appelman</LastName><ForeName>Brent</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Experimental and Molecular Medicine, Amsterdam University Medical Centers, Amsterdam Institute for Infection and Immunity (AII), University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Vugt</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Amsterdam University Medical Centers, Location AMC, Amsterdam Institute for Infection and Immunity (AII), University of Amsterdam, Amsterdam Public Health, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalverda</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department Pulmonary Medicine, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smeele</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department Pulmonary Medicine, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Josien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department Pulmonary Medicine, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiersinga</LastName><ForeName>Willem Joost</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Center for Experimental and Molecular Medicine, Amsterdam University Medical Centers, Amsterdam Institute for Infection and Immunity (AII), University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Amsterdam University Medical Centers, Location AMC, Amsterdam Institute for Infection and Immunity (AII), University of Amsterdam, Amsterdam Public Health, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rostila</LastName><ForeName>Mikael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Health Equity Studies, Stockholm University/Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prins</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Amsterdam University Medical Centers, Location AMC, Amsterdam Institute for Infection and Immunity (AII), University of Amsterdam, Amsterdam Public Health, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam (GGD), Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stronks</LastName><ForeName>Karien</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Public and Occupational Health, Amsterdam Public Health, University of Amsterdam Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Urban Mental Health, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norredam</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section for Health Services Research, Department of Public Health, Research Centre for Migration, Ethnicity and Health (MESU), University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Copenhagen University Hospital, Amager and Hvidovre, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agyemang</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Public and Occupational Health, Amsterdam Public Health, University of Amsterdam Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health Eur</MedlineTA><NlmUniqueID>101777707</NlmUniqueID><ISSNLinking>2666-7762</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ethnicity</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">Transients and migrants</Keyword></KeywordList><CoiStatement>B.A. and M.v.V. report Patient Led Research Collaboration (PLRC) grant paid to the host institution. W.J.W. reports consultancy fees from Pfizer, GSK, and AstraZeneca paid to the host institution, as well as being a member of GSK data and safety monitoring board (fees paid to host institution). All other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>10</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37261215</ArticleId><ArticleId IdType="pmc">PMC10079482</ArticleId><ArticleId IdType="doi">10.1016/j.lanepe.2023.100630</ArticleId><ArticleId IdType="pii">S2666-7762(23)00049-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226(9):1593&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid&#x2014;mechanisms, risk factors, and management. BMJ. 2021;374:n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A., Jayadevan R., Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr. 2021;15(3):869&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Collard D., Stronks K., Harris V., et al. Ethnic differences in coronavirus disease 2019 hospitalization and hospital outcomes in a multiethnic population in the Netherlands. Open Forum Infect Dis. 2022;9(6):ofac257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129177</ArticleId><ArticleId IdType="pubmed">35783684</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur R., Rentsch C.T., Morton C.E., et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021;397(10286):1711&#x2013;1724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8087292</ArticleId><ArticleId IdType="pubmed">33939953</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyer L., Boyd A., Schinkel J., et al. Differences in SARS-CoV-2 infections during the first and second wave of SARS-CoV-2 between six ethnic groups in Amsterdam, the Netherlands: a population-based longitudinal serological study. Lancet Reg Health Europe. 2022;13:100284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8668416</ArticleId><ArticleId IdType="pubmed">34927120</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilunga F.P., Stoeldraijer L., Agyemang C., Stronks K., Harmsen C., Kunst A.E. Inequalities in COVID-19 deaths by migration background during the first wave, interwave period and second wave of the COVID-19 pandemic: a closed cohort study of 17 million inhabitants of the Netherlands. J Epidemiol Community Health. 2023;77:9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">36316152</ArticleId></ArticleIdList></Reference><Reference><Citation>Katikireddi S.V., Lal S., Carrol E.D., et al. Unequal impact of the COVID-19 crisis on minority ethnic groups: a framework for understanding and addressing inequalities. J&#xa0;Epidemiol Community Health. 2021;75(10):970&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8458062</ArticleId><ArticleId IdType="pubmed">33883198</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E.J., Williams D.M., Walker A.J., et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13(1):3528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Alders M. Statistic Netherlands, paper for the conference &#x201c;The measure and mismeasure of populations the statistical use of ethnic and racial categories in multicultural societies&#x201d;. 2001. Classification of the population with a foreign background in the Netherlands; p. 18. Paris.</Citation></Reference><Reference><Citation>de Bruin S., Bos L.D., van Roon M.A., et al. Clinical features and prognostic factors in Covid-19: a prospective cohort study. eBioMedicine. 2021;67:103378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8118723</ArticleId><ArticleId IdType="pubmed">34000622</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellinga A., Cormican M., Hanahoe B., Bennett K., Murphy A.W. Opt-out as an acceptable method of obtaining consent in medical research: a short report. BMC Med Res Methodol. 2011;11(1):1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079702</ArticleId><ArticleId IdType="pubmed">21470399</ArticleId></ArticleIdList></Reference><Reference><Citation>Oudhof K., Harmsen C. De maatschappelijke situatie van Surinaamse bevolkingsgroepen in Nederland. Bevolkingstrends 2011: 46&#x2013;60, Statistics Netherlands. https://www.cbs.nl/nl-nl/achtergrond/2011/51/de-maatschappelijke-situatie-van-surinaamse-bevolkingsgroepen-in-nederland Available at.</Citation></Reference><Reference><Citation>Honaker J., King G., Blackwell M. Amelia II: a program for missing data. J&#xa0;Stat Softw. 2011;45:1&#x2013;47.</Citation></Reference><Reference><Citation>Ballering A.V., van Zon S.K., Olde Hartman T.C., Rosmalen J.G., Lifelines Corona Research Initiative Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynberg E., van Willigen H.D.G., Dijkstra M., et al. Evolution of coronavirus disease 2019 (COVID-19) symptoms during the first 12 months after illness onset. Clin Infect Dis. 2021;75(1):e482&#x2013;e490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522402</ArticleId><ArticleId IdType="pubmed">34473245</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns M., George S., Taburyanskaya M., Poon Y.K. A&#xa0;review of the evidence for corticosteroids in COVID-19. J&#xa0;Pharm Pract. 2022;35(4):626&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">33719698</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy S., Kolloli A., Kumar R., et al. Comprehensive analysis of disease pathology in immunocompetent and immunocompromised hosts following pulmonary SARS-CoV-2 infection. Biomedicines. 2022;10(6):1343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9219777</ArticleId><ArticleId IdType="pubmed">35740365</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox E.D., Hoffmann S.C., DiMercurio B.S., et al. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-61. Transplantation. 2001;72(4):720&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">11544437</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Liu X., Zhou Y., et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9(7):747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099316</ArticleId><ArticleId IdType="pubmed">33964245</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Wang F., Shen Y., et al. Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. JAMA Netw Open. 2021;4(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482055</ArticleId><ArticleId IdType="pubmed">34586367</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.-H., Chen Y., Wang Q.-H., et al. One-year trajectory of cognitive changes in older survivors of COVID-19 in Wuhan, China: a longitudinal cohort study. JAMA Neurol. 2022;79(5):509&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8905512</ArticleId><ArticleId IdType="pubmed">35258587</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J., Waterboer T., Hippchen T., et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis. 2022;74(7):1191&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Guijarro C., P&#xe9;rez-Fern&#xe1;ndez E., Gonz&#xe1;lez-Pi&#xf1;eiro B., et al. Differential risk for COVID-19 in the first wave of the disease among Spaniards and migrants from different areas of the world living in Spain. Rev Clin Esp (Barc) 2021;221(5):264&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">33998512</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerkhoff T.J., Charlton B.T., Appelman B., van Vugt M., W&#xfc;st R.C. Post COVID-19 condition: critical need for a clear definition and detailed pathophysiology. J&#xa0;Cachexia Sarcopenia Muscle. 2022;13(6):2754&#x2013;2756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9745497</ArticleId><ArticleId IdType="pubmed">36251474</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Public Health and the Environment  . 2022. Long covid.https://www.rivm.nl/en/coronavirus-covid-19/long-covid Available at.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>